Evaluating the Cost-Effectiveness of Liquid Biopsy for Diagnosing Burkitt Lymphoma in Pediatric and Young Adult Populations: A Health Economic Study in Tanzania - Takeaways - MDSpire

Evaluating the Cost-Effectiveness of Liquid Biopsy for Diagnosing Burkitt Lymphoma in Pediatric and Young Adult Populations: A Health Economic Study in Tanzania

  • By

  • Jingjing Jiang

  • Liz Morrell

  • Malale Tungu

  • William F. Mawalla

  • Clara Chamba

  • Lulu Chirande

  • Heronima J. Kashaigili

  • Elifuraha Mkwizu

  • Paul S. Ntemi

  • Godlove Sandi

  • Kristin Schroeder

  • Anna Schuh

  • George M. Ruhago

  • Sarah Wordsworth

  • February 21, 2026

  • 0 min

Share

  • 1

    Burkitt Lymphoma is a prevalent childhood cancer in sub-Saharan Africa, with high incidence rates and poor survival outcomes compared to high-income countries.

  • 2

    Current diagnostic methods for Burkitt Lymphoma in Tanzania involve invasive biopsies, leading to delays and misdiagnoses due to limited healthcare resources.

  • 3

    Liquid biopsy offers a non-invasive alternative for diagnosing Burkitt Lymphoma, utilizing ctDNA from blood samples for quicker and more accurate results.

  • 4

    The AI-REAL project established DNA sequencing capabilities in East Africa, validating liquid biopsy for Burkitt Lymphoma diagnosis in children and young adults.

  • 5

    A cost-effectiveness analysis is underway to evaluate the economic benefits of liquid biopsy compared to traditional diagnostic methods for Burkitt Lymphoma.

Original Source(s)

Related Content